Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spyro Mousses

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Molecular Cancer Therapeutics|March 27, 2003
Harnessing the power of RNA interference to advance anticancer drug developmentSpyro Mousses
Annals of the New York Academy of Sciences|January 31, 2004
Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cellsNatasha J Caplen, Spyro Mousses
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2007
Validation of short interfering RNA knockdowns by quantitative real-time PCRSukru Tuzmen, Jeff Kiefer, Spyro Mousses
Biotechniques|September 30, 2003
Integration of genomic technologies for accelerated cancer drug developmentMark Basik, Spyro Mousses, Jeffrey Trent
Cancer Biomarkers : Section a of Disease Markers|November 4, 2010
Elevated expression of the cytochrome b561, a neuroendocrine vesicle protein, in castration resistant prostate tumorsAnjali Srivastava, Spyro Mousses, Albert Dobi, et al.
Drug Discovery Today. Technologies|July 2, 2014
Genome scale cytometry: High content analysis for high throughput RNAi phenotype profilingDavid M Evans, David O Azorsa, Spyro Mousses
Cancer Cell|July 4, 2009
Pancreatic cancer--could it be that simple? A different context of vulnerabilityDaniel D Von Hoff, Ron Korn, Spyro Mousses
Fertility and Sterility|June 9, 2006
Identification of molecular markers for endometriosis in blood lymphocytes by using deoxyribonucleic acid microarraysIdhaliz Flores, Elizabeth Rivera, Spyro Mousses, et al.
Seminars in Oncology|August 8, 2006
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agentsHong Wang, Haiyong Han, Spyro Mousses, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 5, 2011
RNAi-based functional pharmacogenomicsSukru Tuzmen, Pinar Tuzmen, Shilpi Arora, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|March 27, 2003
Harnessing the power of RNA interference to advance anticancer drug developmentSpyro Mousses
Annals of the New York Academy of Sciences|January 31, 2004
Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cellsNatasha J Caplen, Spyro Mousses
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2007
Validation of short interfering RNA knockdowns by quantitative real-time PCRSukru Tuzmen, Jeff Kiefer, Spyro Mousses
Biotechniques|September 30, 2003
Integration of genomic technologies for accelerated cancer drug developmentMark Basik, Spyro Mousses, Jeffrey Trent
Cancer Biomarkers : Section a of Disease Markers|November 4, 2010
Elevated expression of the cytochrome b561, a neuroendocrine vesicle protein, in castration resistant prostate tumorsAnjali Srivastava, Spyro Mousses, Albert Dobi, et al.
Drug Discovery Today. Technologies|July 2, 2014
Genome scale cytometry: High content analysis for high throughput RNAi phenotype profilingDavid M Evans, David O Azorsa, Spyro Mousses
Cancer Cell|July 4, 2009
Pancreatic cancer--could it be that simple? A different context of vulnerabilityDaniel D Von Hoff, Ron Korn, Spyro Mousses
Fertility and Sterility|June 9, 2006
Identification of molecular markers for endometriosis in blood lymphocytes by using deoxyribonucleic acid microarraysIdhaliz Flores, Elizabeth Rivera, Spyro Mousses, et al.
Seminars in Oncology|August 8, 2006
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agentsHong Wang, Haiyong Han, Spyro Mousses, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 5, 2011
RNAi-based functional pharmacogenomicsSukru Tuzmen, Pinar Tuzmen, Shilpi Arora, et al.
Pageof 5